Insulet (STU:GOV) Beta: 1.2793 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GOV Insulet Corp STU:GOV
77 GF Score
Price €143.40
GF Value €348.98
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Beta?

Insulet STU:GOV -0.10% 77 Beta is 1.2793 as of Aug. 02, 2026. GuruFocus rates STU:GOV with a GF Score™ of 77/100 and a GF Value™ of €348.98 (Significantly Undervalued).

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-02), Insulet's Beta is 1.2793.


Insulet  (STU:GOV) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Insulet Beta Related Terms


Insulet Beta Historical Data

* Premium members only.

The historical data trend for Insulet's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Beta Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.59 1.42 0.55 0.70

Insulet Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 1.55 1.78 0.70 1.72

STU:GOV vs GMED, PEN, BRKR: Beta Comparison

For the Medical Devices subindustry, Insulet's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Beta distribution charts can be found below:

* The bar in red indicates where Insulet's Beta falls into.


STU:GOV
77GF Score
Insulet Corp STU:GOV
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.2793 mean?
Insulet (STU:GOV) has a Beta of 1.2793 as of Aug. 02, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Insulet and its competitors.
Is Insulet's Beta too high?
Insulet's current Beta is 1.2793. Overall, Insulet has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Beta compare to GMED and PEN?
Insulet's Beta of 1.2793 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Insulet and its competitors. Insulet's current Beta is 1.2793. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (STU:GOV) is currently considered Significantly Undervalued. The stock's GF Value™ is €348.98, compared to a current price of €143.40 — trading 58.9% below its estimated fair value. The current Beta is 1.2793. Insulet's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Insulet (STU:GOV), the current Beta is 1.2793 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (STU:GOV) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of €143.40 is trading 58.9% below its estimated GF Value™ of €348.98. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for STU:GOV:

  • Beta: 1.2793
  • GF Value™: €348.98 vs. price of €143.40 (58.9% below fair value)
  • GF Score™: 77/100

No single metric tells the full story. See the STU:GOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
77GF Score

Get the complete analysis for STU:GOV

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.40
Price
€348.98
GF Value